Company profile for Exicure

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based o...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
8045 Lamon Avenue Suite 410 Skokie, IL 60077
Telephone
Telephone
847.673.1700
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/07/3183943/33289/en/Exicure-Inc-Reports-Third-Quarter-2025-Financial-Results.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179373/33289/en/New-Burixafor-Clinical-Data-to-be-Presented-as-an-Oral-Presentation-at-the-2025-ASH-Annual-Meeting.html

GLOBENEWSWIRE
03 Nov 2025

https://www.globenewswire.com/news-release/2025/10/06/3161574/33289/en/Exicure-Highlights-Recent-Achievements-and-Near-term-Strategic-Priorities.html

GLOBENEWSWIRE
06 Oct 2025

https://www.businesswire.com/news/home/20250808672096/en/Exicure-Inc.-Reports-Second-Quarter-2025-Financial-Results

BUSINESSWIRE
08 Aug 2025
Exicure Regains Nasdaq Filing Compliance
Exicure Regains Nasdaq Filing Compliance

04 Aug 2025

// BUSINESSWIRE

https://www.businesswire.com/news/home/20250804787056/en/Exicure-Inc.-Nasdaq-XCUR-Regains-Compliance-with-Nasdaq-Filing-Requirements

BUSINESSWIRE
04 Aug 2025

https://www.businesswire.com/news/home/20250801325070/en/Exicure-Completes-the-Last-Patient-Last-Visit-in-Phase-2-Study-of-GPC-100-for-Stem-Cell-Mobilization-in-Multiple-Myeloma-Patients-Undergoing-Autologous-Transplant

BUSINESSWIRE
01 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty